ASTS
AST SpaceMobile, Inc.
ASTS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
CLSK
CleanSpark, Inc.
There isn't enough reported data to score CLSK yet.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CLSK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Weak |
CLSK's revenue is currently healthy, but its profitability and balance sheet are weak. There isn't enough data to rate its cash flow.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
CLSK PE Valuation
CLSK has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CLSK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CLSK's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS has the edge over CLSK on earnings, with more consistent year-over-year improvement.
CLSK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.80 | -614% |
| Q1 2026 | -$2.09 | -$1.02 |
| Q4 2025 | -$1.06 | -$1.06 |
| Q3 2025 | $1.12 | +$1.81 |
| Q2 2023 | -$1.77 | -$1.25 |
| Q1 2023 | -$2.36 | -$2.06 |
| Q4 2022 | -$2.13 | -$2.05 |
| Q3 2022 | -$1.35 | -$0.60 |
CLSK has swung to a loss: it lost $3.80 per share over the past year, after a profit the year before.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the stronger quarterly revenue trend. Revenue is up 187% for ASTS versus up 70% for CLSK.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
CLSK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $89.3M | +70% |
| Q2 2024 | $104.1M | +129% |
| Q1 2024 | $111.8M | +163% |
| Q4 2023 | $73.8M | +165% |
| Q3 2023 | $52.5M | +101% |
| Q2 2023 | $45.5M | +47% |
| Q1 2023 | $42.5M | +2.2% |
| Q4 2022 | $27.8M | -33% |
CLSK's revenue has grown year over year for seven quarters in a row: $89M last quarter, up 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -73% | +58 points |
| Q2 2024 | -239% | -205 points |
| Q1 2024 | 123% | +164 points |
| Q4 2023 | 39% | +143 points |
| Q3 2023 | -132% | +24 points |
| Q2 2023 | -34% | +14 points |
| Q1 2023 | -41% | -49 points |
| Q4 2022 | -104% | -115 points |
CLSK's operating margin was −73% last quarter, up 58 points from the same quarter a year ago.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
CLSK has the stronger cash trend. Its trailing FCF is down 283% versus its history, compared with ASTS at down 363%.
CLSK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$118.4M | -$8.5M |
| Q1 2026 | -$173.4M | -$61.1M |
| Q4 2025 | -$198.1M | -$78.6M |
| Q2 2025 | -$109.9M | -$31.5M |
| Q1 2025 | -$112.3M | -$53.9M |
| Q4 2024 | -$119.5M | -$51.9M |
| Q3 2024 | -$95.5M | -$32.7M |
| Q2 2024 | -$78.3M | -$59.1M |
CLSK has burned cash in most quarters: −$600M over the past year, against −$406M the year before.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
CLSK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.1% | -11M shares |
| 1 year | -21% | -68.8M shares |
| 3 years | +287% | +190M shares |
| 5 years | +4901% | +252M shares |
CLSK has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $460M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $145M |
CLSK spent $460M buying back its own shares over the past year.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CLSK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 150.4x | High |
| Q4 2025 | 7.4x | High |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q4 2024 | 1.6x | Healthy |
| Q3 2024 | -20.5x | Net Cash |
| Q2 2024 | -14.8x | Net Cash |
| Q1 2024 | -1.4x | Net Cash |
CLSK's net debt is more than 20 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
CLSK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CLSK's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
CLSK PE vs Technology Sector
| Metric | CLSK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CLSK has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over CLSK on trend strength, trading above more of its moving averages.
CLSK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.27 | 26% below |
| 20 week MA | $11.5 | 40% below |
| 50 week MA | $12.0 | 43% below |
| 100 week MA | $11.5 | 41% below |
| 200 week MA | $10.5 | 35% below |
CLSK is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
CLSK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.2 | $24.9 | +54% |
| 2021 | $24.9 | $11.9 | -52% |
| 2022 | $11.9 | $1.97 | -83% |
| 2023 | $1.97 | $11.0 | +460% |
| 2024 | $11.0 | $9.78 | -11% |
| 2025 | $9.78 | $10.9 | +12% |
| 2026 YTD | $10.9 | $6.84 | -37% |
CLSK has the edge over ASTS on returns for 2026, with the stronger performance.